We invite you to participate in a multicenter observational study entitled:
Effectiveness and safety of brentuximab vedotin (BV) consolidation therapy in patients with Hodgkin lymphoma (HL) who underwent autologous stem cell transplantation (ASCT). Prospective, multicenter observational study, which aims to determine progression-free survival (PFS) and the clinical and demographic characteristics of patients with Hodgkin lymphoma (HL), including best response to first-line treatment, time to progression, and predictors of high risk of progression.
To start the study, it is necessary to conclude an online agreement. Therefore, please register and follow the instructions appearing on the computer screen.
After successful registration and signing of the electronic agreement, please log in with the data obtained during the account creation process.